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background:  Depressed cardiac output stimulates release of arginine vasopressin (AVP), but the relationship is not extensively examined between 
AVP levels and cardiac parameters especially in patients with stage D heart failure (HF). For stage D HF, ventricular assist device (VAD) implantation 
or heart transplantation (HTx) is the only established option to improve prognosis, but little is known whether such definitive treatment can alter AVP 
levels.
Methods:  Data were obtained on the admission day from 130 in-hospital patients with stage D HF. Data were also collected from 82 patients who 
received VAD (N=46) or HTx (N=36) at 3 months after the operation. Plasma AVP concentration was measured after being at spine position for more 
than 15 minutes. All patients were followed at our institute between Jul 2011 and Nov 2013.
results:  Plasma levels of AVP were considerably high (6.4±6.0 pg/mL) and negatively correlated with serum sodium concentration (s-Na, 
134.6±5.6 mEq/L, r=-0.542*) in patients with stage D HF (N=130). Higher AVP levels also associated with lower cardiac index (CI, 2.2±0.5 L/min/
m2, r=-0.385*) as well as higher levels of plasma BNP (748.1±768.2 pg/mL, r=0.384*) in them. After VAD/HTx treatment (N=82), improvement of 
CI (2.6±0.5 L/min/m2* vs. HF) was accompanied by normalization of s-Na (139.2±2.3 mEq/L* vs. HF), suppressed release of AVP (1.7±3.4 pg/
mL* vs. HF), and decreased BNP levels (118.1±160.4 pg/mL* vs. HF). Interestingly, plasma AVP levels positively correlated with s-Na in VAD/HTx 
group (r=0.531*), but no correlation was observed with CI or BNP levels. AVP ≥5.3 pg/mL well predicted poor prognosis over 2 years in HF group (all 
survival: 58%* vs. 82%; VAD-free survival: 36%* vs. 78%) (*p<0.01).
conclusions:  In patients with stage D HF, low cardiac output stimulates AVP release probably via a non-osmotic way that results in hyponatremia. 
Consistently with the recent sub-analysis of EVEREST study, higher AVP is a predictor of poor prognosis among stage D HF patients. After sufficient 
recovery of cardiac output by VAD/HTx therapy, AVP release is suppressed and is mainly regulated by serum osmolality.
